JP2020518668A - ｘＣＴ抗体に関連する組成物および方法 - Google Patents

ｘＣＴ抗体に関連する組成物および方法 Download PDF

Info

Publication number
JP2020518668A
JP2020518668A JP2020511734A JP2020511734A JP2020518668A JP 2020518668 A JP2020518668 A JP 2020518668A JP 2020511734 A JP2020511734 A JP 2020511734A JP 2020511734 A JP2020511734 A JP 2020511734A JP 2020518668 A JP2020518668 A JP 2020518668A
Authority
JP
Japan
Prior art keywords
antibody
xct
cancer
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518668A5 (cg-RX-API-DMAC7.html
Inventor
フェデリカ ペリクレ
フェデリカ ペリクレ
ジョン オルーク
ジョン オルーク
フェデリカ カバロ
フェデリカ カバロ
Original Assignee
アジルバックス インコーポレイテッド
アジルバックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジルバックス インコーポレイテッド, アジルバックス インコーポレイテッド filed Critical アジルバックス インコーポレイテッド
Publication of JP2020518668A publication Critical patent/JP2020518668A/ja
Publication of JP2020518668A5 publication Critical patent/JP2020518668A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020511734A 2017-05-01 2018-04-30 ｘＣＴ抗体に関連する組成物および方法 Pending JP2020518668A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492912P 2017-05-01 2017-05-01
US62/492,912 2017-05-01
PCT/US2018/030276 WO2018204278A1 (en) 2017-05-01 2018-04-30 COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2020518668A true JP2020518668A (ja) 2020-06-25
JP2020518668A5 JP2020518668A5 (cg-RX-API-DMAC7.html) 2020-10-15

Family

ID=64016266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511734A Pending JP2020518668A (ja) 2017-05-01 2018-04-30 ｘＣＴ抗体に関連する組成物および方法

Country Status (7)

Country Link
US (1) US11059901B2 (cg-RX-API-DMAC7.html)
EP (1) EP3618869A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020518668A (cg-RX-API-DMAC7.html)
CN (1) CN111194222A (cg-RX-API-DMAC7.html)
AU (1) AU2018261720A1 (cg-RX-API-DMAC7.html)
CA (1) CA3060590A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018204278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
WO2021168283A1 (en) * 2020-02-19 2021-08-26 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
JP2024542030A (ja) 2021-10-29 2024-11-13 ブイアイビー ブイゼットダブリュ 慢性創傷治癒のための手段および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
WO2003101388A2 (en) * 2002-05-30 2003-12-11 Bristol-Myers Squibb Company Human solute carrier family 7 member 11 (hslc7a11)
EP2239577A1 (en) * 2009-04-07 2010-10-13 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma
CN102719521B (zh) * 2011-03-31 2015-12-02 上海市肿瘤研究所 胱氨酸/谷氨酸反向转体xCT抑制剂在肝癌治疗中的应用
US10584161B2 (en) * 2015-09-21 2020-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for heartland virus and methods of their use
WO2017106806A1 (en) * 2015-12-18 2017-06-22 Federica Cavallo COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
CN105837686B (zh) * 2016-05-27 2020-08-28 洛阳普泰生物技术有限公司 一种单克隆抗体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOLECULAR NEUROSCIENCE, 2008, VOL.19, NO.16, P.1589-1592, JPN6021027183, ISSN: 0004724742 *
SCIENCE, 2006, VOL.311, P.1921-1924, JPN6021027180, ISSN: 0004724740 *
THE JOURNAL OF COMPARATIVE NEUROLOGY, 2016, VOL.524, P.1015-1032, JPN6021027181, ISSN: 0004724741 *

Also Published As

Publication number Publication date
AU2018261720A1 (en) 2019-11-07
EP3618869A4 (en) 2021-01-20
CA3060590A1 (en) 2018-11-08
US11059901B2 (en) 2021-07-13
WO2018204278A1 (en) 2018-11-08
US20200148784A1 (en) 2020-05-14
EP3618869A1 (en) 2020-03-11
CN111194222A (zh) 2020-05-22

Similar Documents

Publication Publication Date Title
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
ES2927090T3 (es) Anticuerpo anti-TROP-2 humano que muestra actividad antitumoral in vivo
CN101939336B (zh) Axl抗体
DK2760471T3 (en) THERAPEUTIC PEPTIDES
JP7629651B2 (ja) Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
ES2469369T3 (es) Anticuerpos anti-CXCR4 humanizados para el tratamiento del cáncer
JP7279761B2 (ja) 卵巣癌の検出および治療のための組成物および方法
EA035852B1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
EP2876114A1 (en) Antibodies against CCR9 and applications thereof
JP7478708B2 (ja) 胃癌の検出および治療のための組成物および方法
JP2022529232A (ja) 抗ｈｅｒ２結合分子
JP2020518668A (ja) ｘＣＴ抗体に関連する組成物および方法
JP6159010B2 (ja) テトラスパニン８に対するハイブリドーマクローンおよびモノクローナル抗体
US11040223B2 (en) Compositions and methods related to xCT peptides
US20150203582A1 (en) Method of generating antibodies
US20220098328A1 (en) Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
KR20250123919A (ko) 항-tgf베타 수용체 1 항체 및 그의 용도
JP2023169439A (ja) 抗ヒトｔｒｐｖ２抗体
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200904

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220310